Literature DB >> 12853550

Inhalation challenge with bovine dander allergens: who needs it?

Heikki Koskela1, Antti Taivainen, Hannu Tukiainen, Hak-Kim Chan.   

Abstract

STUDY
OBJECTIVES: To identify which tests would be useful in selecting patients for a specific inhalation challenge with bovine dander allergens (bSIC).
DESIGN: A prospective study.
SETTING: A university hospital. PATIENTS: Thirty-seven dairy farmers with a clinical suspicion of occupational asthma due to bovine allergens.
INTERVENTIONS: Each patient (n = 27) underwent histamine challenge, mannitol challenge, exhaled nitric oxide (NO) measurement, bovine-specific serum IgE measurement, and skin-prick test (SPT) with bovine allergens prior to undergoing a bSIC.
RESULTS: Eleven patients responded to the inhalation challenge with bovine allergens. The sensitivity and specificity of the tests, based on this response, were 82% and 65%, respectively, for the histamine challenge; 20% and 94%, respectively, for the mannitol challenge; 27% and 77%, respectively, for the NO measurement; 82% and 100%, respectively, for the bovine-specific serum IgE measurement; and 100% and 50%, respectively, for the SPT. Multiple regression analysis revealed that only IgE-mediated sensitivity to bovine allergens, but neither bronchial hyperreactivity nor exhaled NO concentration, contributed significantly to the response.
CONCLUSION: Only the SPT with bovine allergens and bovine-specific serum IgE measurements were useful in selecting patients for the bSIC. This challenge should not be performed in SPT-negative subjects. A diagnosis of occupational asthma due to bovine dander allergens could be made without an inhalation challenge test in asthmatic patients with high bovine-specific serum IgE levels. This practice would eliminate the need for the majority of bSICs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853550     DOI: 10.1378/chest.124.1.383

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  4 in total

Review 1.  Overview of serological-specific IgE antibody testing in children.

Authors:  Linda Cox
Journal:  Curr Allergy Asthma Rep       Date:  2011-12       Impact factor: 4.806

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

Review 3.  Evidence based guidelines for the prevention, identification, and management of occupational asthma.

Authors:  P J Nicholson; P Cullinan; A J Newman Taylor; P S Burge; C Boyle
Journal:  Occup Environ Med       Date:  2005-05       Impact factor: 4.402

4.  Diagnostic approach in cases with suspected work-related asthma.

Authors:  Tor B Aasen; P Sherwood Burge; Paul K Henneberger; Vivi Schlünssen; Xaver Baur
Journal:  J Occup Med Toxicol       Date:  2013-06-14       Impact factor: 2.646

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.